Chikungunya

Das Chikungunya-Virus ist in den Tropen und Subtropen weit verbreitet und verursacht immer wieder überregionale Ausbrüche des Chikungunya-Fiebers. Der Klimawandel und die Globalisierung von Handel und Reisen haben zu einer Ausweitung des Lebensraums der Überträgermücke geführt. Eine antivirale Behandlung gibt es nicht. Deshalb sind Überwachung und Vektorkontrolle unerlässlich, um ein erneutes Auftreten und Epidemien zu verhindern.

Schlüsselwörter

Chikungunya - Pathophysiologie - Immunologie - Therapie - Prävention

• Literatur

• 1 Azar SR, Campos RK, Bergren NA. et al. Epidemic alphaviruses: ecology, emergence and outbreaks. Microorganisms 2020; 8: 1167
• 2 Bartholomeeusen K, Daniel M, LaBeaud DA. et al. Chikungunya fever. Nat Rev Dis Primers 2024; 9: 17
• 3 Kramer IM, Pfeiffer M, Steffens O. et al. The ecophysiological plasticity of Aedes aegypti and Aedes albopictus concerning overwintering in cooler ecoregions is driven by local climate and acclimation capacity. Sci Total Environ 2021; 778: 146128
• 4 Zaid A, Burt FJ, Liu X. et al. Arthritogenic alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet Infect Dis 2021; 21: e123-e133
• 5 Mehand MS, Al-Shorbaji F, Millett P. et al. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antivir Res 2018; 159: 63-67
• 6 Kolimenakis A, Heinz S, Wilson ML. et al. The role of urbanisation in the spread of Aedes mosquitoes and the diseases they transmit – a systematic review. PLoS Negl Trop Dis 2021; 15: e0009631
• 7 de Lima Cavalcanti TYV, Pereira MR, de Paula SO. et al. A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses 2022; 14: 969
• 8 Tsetsarkin KA, Weaver SC. Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. PLoS Pathog 2011; 7: e1002412
• 9 Nsoesie EO, Kraemer MUG, Golding N. et al. Global distribution and environmental suitability for chikungunya virus 1952 to 2015. Eurosurveillance 2016; 21
• 10 Jelinek T. CRM Handbuch Reisemedizin 2025. Düsseldorf: CRM Centrum für Reisemedizin; 2024
• 11 Hoornweg TE, van Duijl-Richter MKS, Nuñez NVA. et al. Dynamics of chikungunya virus cell entry unraveled by single-virus tracking in living cells. J Virol 2016; 90: 4745-4756
• 12 Pingen M, Bryden SR, Pondeville E. et al. Host inflammatory response to mosquito bites enhances the severity of Arbovirus infection. Immunity 2016; 44: 1455-1469
• 13 Hoarau JJ, Jaffar Bandjee MC, KreibichTrotot P. et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 2010; 184: 5914-5927
• 14 Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev Rheumatol 2019; 15: 597-611
• 15 Economopoulou A, Dominguez M, Helynck B. et al. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Réunion. Epidemiol Infect 2009; 137: 534-541
• 16 Rodríguez-Morales AJ, Cardona-Ospina J, Urbano-Garzón SF. et al. Prevalence of post-chikungunya infection chronic inflammatory arthritis: a systematic review and meta-analysis. Arthritis Care Res 2016; 68: 1849-1858
• 17 Paixão ES, Rodrigues LC, da Conceição N Costa M. et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg 2018; 112: 301-316
• 18 Moreira J, Brasil P, Dittrich S. et al. Mapping the global landscape of chikungunya rapid diagnostic tests: a scoping review. PLoS Negl Trop Dis 2022; 16: e0010067
• 19 Webb E, Michelen M, Rigby I. et al. An evaluation of global Chikungunya clinical management guidelines: a systematic review. EClinicalMedicine 2022; 54: 101672
• 20 Zaid A, Gérardin P, Taylor A. et al. Chikungunya arthritis: implications of acute and chronic inflammation mechanisms on disease management. Arthritis Rheumatol 2018; 70: 484-495
• 21 Antunes de Brito CA, von Sohsten AKA, de Sá Leitão CC. et al. Pharmacologic management of pain in patients with Chikungunya: a guideline. Rev Soc Bras Med Trop 2016; 49: 668-679
• 22 World Health Organization (WHO). Guidelines on clinical management of Chikungunya fever. New Delhi (India): World Health Organization; 2008. Accessed November 10, 2024 at: https://iris.who.int/bitstream/handle/10665/205178/B3234.pdf
• 23 Javelle E, Ribera A, Degasne I. et al. Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006–2012. PLoS Negl Trop Dis 2015; 9: e0003603
• 24 Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study. Clin Rheumatol 2017; 36: 1335-1340
• 25 Doran C, Gerstenbluth I, Duits A. et al. The clinical manifestation and the influence of age and comorbidities on long-term chikungunya disease and health-related quality of life: a 60-month prospective cohort study in Curaçao. BMC Infect Dis 2022; 22: 948
• 26 Valneva. Valneva initiates rolling submission of FDA biologics license application for its single-shot Chikungunya vaccine candidate, 2022. Accessed November 10, 2024 at: https://valneva.com/press-release/valneva-initiates-rolling-submission-of-fda-biologics-license-application-for-its-single-shot-chikungunya-vaccine-candidate/
• 27 Bennett SR, McCarty JM, Ramanathan R. et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis 2022; 22: 1343-1355
• 28 Babaeimarzangou SS, Zaker H, Soleimannezhadbari E. et al. Vaccine development for zoonotic viral diseases caused by positive-sense single-stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review). Exp Ther Med 2022; 25: 42
• 29 Malonis RJ, Earnest JT, Kim AS. et al. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses. Proc Natl Acad Sci USA 2021; 118: e2100104118
• 30 Ferreira AC. et al. Beyond members of the flaviviridae family, sofosbuvir also inhibits Chikungunya virus replication. Antimicrob Agents Chemother 2019; 63: e01389-e01418